Eli Lilly continues growth with $24.4 billion in Q3 revenue
- 1Eli Lilly shares have risen approximately 6% based on the recent Q3 update.
- 2Eli Lilly recorded $5.4 billion in Q3 Zepbound revenue, achieving a 49% year-over-year growth rate for Zepbound.
- 3Eli Lilly is not just a weight loss drug company and possesses a product portfolio and strong pipeline across various therapeutic areas.
So what's the key point?
Eli Lilly's weight loss drug revenue increased by 49% compared to last year. The stock price has also risen recently because the company has various different medicines.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.